Nuvectis Pharma (NASDAQ: NVCT) announced poster presentations for its clinical candidate NXP900 at the 2026 American Association for Cancer Research Meeting (AACR), April 17–22, 2026 in San Diego, CA.
Three abstracts will be presented April 21–22 covering synergy with KRAS inhibitors in NSCLC, resistance mechanisms in cholangiocarcinoma, and targeting MDSCs via SRC family kinase inhibition. Specific session times and titles are listed for each poster.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – NVCT
+3.20%
+3.20%Session close to close
In the Mar 31 session, NVCT gained 3.20%, reflecting a moderate positive market reaction.
This announcement highlights multiple NXP900-focused posters at the 2026 AACR meeting, emphasizing c...
Analysis
This announcement highlights multiple NXP900-focused posters at the 2026 AACR meeting, emphasizing combination strategies, drug resistance mechanisms, and immunomodulation in NSCLC. It builds on prior Phase 1b progress and earlier AACR-related data, reinforcing NXP900 as the core asset. In context of a share price around 7.49 and cash runway into 2027, investors may watch for how these data influence future trial designs, partnering interest, and potential use of the existing $150,000,000 shelf registration.
Initial Q3 2025 financials plus Phase 1b progress and AACR-NCI-EORTC posters.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent NVCT news around NXP900 and earnings has produced mixed reactions, with some clinical and event updates aligning with modest gains while several earnings-related releases coincided with noticeable declines.
Recent Company History
Over the last six months, Nuvectis has focused updates on NXP900 and its financial runway. Earnings releases in November 2025 and February 2026 highlighted rising R&D spend and cash extending into 2H-2027, but drew varied price responses. Multiple NXP900 milestones – Phase 1b initiation, key opinion leader events, and AACR-related posters – reinforce a steady clinical narrative. Today’s AACR presentation announcement continues that trajectory, emphasizing combination strategies and resistance mechanisms that build on prior preclinical and early clinical disclosures.
Key Terms
yes1/src inhibitor, kras inhibitors, nsclc, sfk inhibitor, +3 more
7 terms
yes1/src inhibitormedical
"NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy"
A yes1/src inhibitor is a drug that blocks the activity of YES1 and related Src family proteins, which act like on/off switches inside cells that tell them to grow, move, or survive. For investors, these inhibitors matter because they are targeted cancer medicines: if they successfully stop tumor signaling in clinical trials and win regulatory approval, they can become valuable therapies, but they also carry trial, safety and competitive risks.
kras inhibitorsmedical
"demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC"
KRAS inhibitors are drugs designed to block the action of a protein produced by the KRAS gene, which can act like a stuck accelerator in some cancer cells and drive uncontrolled growth. For investors, they matter because successful inhibitors can become high-value medicines with large patient demand, but they also carry typical drug-development risks—clinical trial, safety and approval uncertainty—that can sharply affect a drugmaker’s prospects and stock value.
nsclcmedical
"KRAS inhibitors in KRASi sensitive and resistant NSCLC models"
NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.
sfk inhibitormedical
"Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized"
An SFK inhibitor is a drug that blocks a group of proteins called Src family kinases, which act like internal “on/off” switches that tell cells when to grow, move or survive. Investors watch these drugs because they are being developed mainly for cancers and other diseases where those signals are overactive; trial results, safety and regulatory decisions can quickly change a developer’s prospects much like a traffic light changing the flow of cars.
il13ra2-akt signalingmedical
"is characterized by IL13RA2-AKT signaling and can be overcome"
IL13RA2-AKT signaling is a chain of molecular events inside cells where the IL13RA2 receptor, when activated, turns on the AKT protein that controls cell survival, growth and inflammation. Think of it like a switch that activates a circuit determining whether a cell grows, resists death or alters immune behavior. Investors pay attention because drugs that block or modify this signaling can change disease outcomes—especially in certain cancers and inflammatory conditions—affecting clinical trial prospects, regulatory approvals and market value.
myeloid-derived suppressor cells (mdscs)medical
"Targeting myeloid-derived suppressor cells (MDSCs) to restore antitumor immunity"
Myeloid-derived suppressor cells (MDSCs) are a group of immune cells that act like biological brakes, blocking other immune cells from attacking infections or tumors. For investors, MDSCs matter because their presence can make cancers harder to treat and can determine whether immune-based drugs work in clinical trials, so therapies that reduce or reprogram MDSCs can change the outlook and value of biotech assets.
tyrosine kinasemedical
"Session Title Tyrosine Kinase, Phosphatase, and Other Inhibitors Session Date"
A tyrosine kinase is a type of protein that acts like a cellular switch, turning other proteins on or off by attaching a small chemical tag; this helps control cell growth, division and communication much like a traffic light directs cars. Investors watch tyrosine kinases because drugs that block or modify these switches are major targets for therapies—especially in cancer and other growth-related diseases—so progress in related research, trials or approvals can materially affect a company’s prospects and valuation.
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2026 American Association for Cancer Research Meeting (2026 AACR), taking place from April 17th to April 22nd in San Diego, CA.
Abstract Title
Poster Presentation Details
NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC models
Session Title Combination Targeted Therapy
Session Date / Time April 21st, 2:00 PM – 5:00 PM PT
Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy
Session Title Novel Strategies to Reverse Drug Resistance
Session Date / Time April 22nd, 9:00 AM – 12:00 PM PT
Targeting myeloid-derived suppressor cells (MDSCs) to restore antitumor immunity in non-small cell lung cancer (NSCLC) via SRC family kinase Inhibition with NXP900
Session Title Tyrosine Kinase, Phosphatase, and Other Inhibitors
Session Date / Time April 21st, 2:00 PM – 5:00 PM PT
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study in healthy volunteers and the Phase 1b program has been initiated.
For more information on Nuvectis, please visit our website at https://nuvectis.com/.
When will Nuvectis (NVCT) present NXP900 data at the 2026 AACR meeting?
Nuvectis will present NXP900 posters on April 21 and April 22, 2026. According to the company, sessions include presentations April 21 (2:00 PM–5:00 PM PT) and April 22 (9:00 AM–12:00 PM PT) covering combination therapy and resistance topics.
What NXP900 topics will Nuvectis (NVCT) cover at AACR 2026?
Nuvectis will present three NXP900 abstracts on NSCLC synergy with KRAS inhibitors, cholangiocarcinoma resistance, and MDSC targeting. According to the company, these focus on combination strategies, IL13RA2-AKT resistance signaling, and immune modulation via SRC inhibition.
Which session will feature the NXP900 poster on KRAS inhibitor synergy at AACR 2026?
The KRAS inhibitor synergy poster appears in the Combination Targeted Therapy Session on April 21, 2026. According to the company, the session is scheduled 2:00 PM–5:00 PM PT and highlights first-in-class YES1/SRC inhibitor results in NSCLC models.
How does Nuvectis describe resistance to NXP900 in cholangiocarcinoma at AACR 2026?
Nuvectis reports resistance characterized by IL13RA2-AKT signaling and potential reversal by combination therapy. According to the company, the finding will be presented in the Novel Strategies to Reverse Drug Resistance Session on April 22, 2026 (9:00 AM–12:00 PM PT).
Will the Nuvectis (NVCT) AACR posters include preclinical or clinical NXP900 data?
The announcements describe preclinical models and mechanism-focused results for NXP900. According to the company, presented material highlights NSCLC and cholangiocarcinoma model data and immune-modulation studies via SRC family kinase inhibition.
How can investors view Nuvectis (NVCT) NXP900 presentations from AACR 2026?
Poster details will be available at the AACR meeting sessions on April 21–22, 2026. According to the company, attendees can view posters during listed session times; investors should consult AACR or company channels for poster access and subsequent disclosures.
